Introduction
Chronic phase (CP) chronic myelogenous leukemia (CML) originates in a multipotent hematopoietic stem cell, and, at initial stages of disease, is driven by the oncogenic Philadelphia chromosome, the reciprocal translocation t(9;22)(q34;q11) (1), its molecular equivalent the BCR-ABL oncogene and its subsequent derivative, the BCR-ABL1 tyrosine kinase. In the absence of specific treatment, the natural evolution of the disease leads to an inexorable fatal blast crisis. TKI have revolutionized the overall poor prognosis of this disease, particularly in CP, by prolonging, maybe indefinitely, the life of patients (2) . However, it has been demonstrated in vitro that none of the agents available are able to eradicate a pool of living, quiescent, BCR-ABL + undifferentiated cells, that may serve as a reservoir for additional oncogenic events leading to disease progression (3) (4) (5) . These findings have been confirmed in vivo in the vast majority of patients who remain in persistent molecular residual disease thus forbidding TKI cessation 2 . In ~50% of cases of imatinib (IM) resistance in CP, patients acquire, under the selective pressure of TKI, recurrent BCR-ABL amino-acid exchanges (6) (7) (8) which modify the conformation of the ABL tyrosine kinase pocket, and result in the impairment at different levels of the activity of the three TKI most prescribed TKI to date (ie: IM, dasatinib and nilotinib). The T315I BCR-ABL mutation remains the most problematic since it totally impairs contact between the ABL tyrosine kinase domain and these three TKI, resulting in high IC50 to these TKI, as assessed in engineered murine cell lines (9) . These biochemical and cellular in vitro findings are associated with poor survival rates in patients resistant to IM (10) (11) (12) (13) (14) . However, it remains unclear whether in chronic phase the presence of the T315I 6 mutation within the cells confers a specific virulence to the disease or whether it is simply a co-factor in an IM-resistant cell for other unknown reasons.
In this perspective, we further exploited data available from an international registry of patients harboring a T315I mutation previously published in part (14) , by restricting our analyses exclusively to chronic phase CML patients (at diagnosis and at T315I mutation detection), not eligible for allogeneic stem cell transplantation (as this option might rescue a number of them (15)), that have not received ponatinib, and updating the data.
Using a matched pair analysis in our three European centers, we matched CP CML T315I + patients with other CP CML patients IM-resistant, but lacking detectable T315I
BCR-ABL mutation at resistance, in an effort to demonstrate the negative impact of the presence of this mutation on overall and failure-free survival.
Methods

Study Population
CML patients in CP, resistant to TKI according to the IRIS study definitions (2) or ELN recommendations (16, 17) and harboring a T315I BCR-ABL mutation detected prospectively or retrospectively on frozen samples, by any validated means, between 1999 and 2010 were included in this analysis. CP CML patients with T315I mutation were extracted from a previously described updated international database containing 222 T315I + CML (all phases and Ph + ALL) patients (14) . In this latest study (14) , survival of T315I + patients did not differ between countries (unpublished data). In this study, the comparison group was CML patients in CP at diagnosis and at IM-resistance, previously screened at IM-resistance for BCR-ABL mutations and found to be T315I negative (but could harbor other mutations). These T315 -patients were identified in the individual databases from 3 representative European centers (Lyon, Bordeaux, France and London, UK). All allogeneic transplanted patients were eliminated from this study.
Patients with T315I mutation were pair-matched to T315I -IM-resistant patients according to three different variables: age at CP CML diagnosis (± 5 years), elapsed time between CP CML diagnosis and IM-initiation (± 5 years), IM treatment duration (± 31 months). All patients were in CP at diagnosis and at IM-resistance. All these patients are ponatinibfree. These CML patients provided written consent whenever possible. This retrospective analysis was approved by the institutional review board/ethical review committee in each participating site/country whenever necessary.
Data Collection
Demographic, clinical, treatment, mutation, and survival data were collected from each of the 3 European centers for the control group or extracted -and updated whenever possible-from the epidemiological study database previously described (14) . 
Survival Measurement
Survival was analyzed according to the Kaplan-Meier methods and log-rank tests calculated from the dates of IM-initiation, IM-resistance, to death or to the most recent date when the patient was known to be alive. Overall survival (OS) was analyzed since diagnosis, IM-initiation, IM-resistance, and the initiation of second generation TKI (TKI2).
Progression-free survival could not be analyzed precisely since the exact date of progression was not available for all cases, however, it was possible to analyze failurefree survival when considering failure as the time to next treatment, progression or death.
Statistical Analysis
Multivariate analysis, according to the Cox proportional hazard model adjusted on OS was performed on the whole population of patients and on the T315I + subgroup.
exposure to interferon, intervals between CML diagnosis and IM-initiation, IM-initiation and IM-resistance, and exposure to TKI2. These variables were identified as being significant in an initial univariate analysis. Age was a continuous variable, whereas T315I mutation status, gender, Interferon-α, TKI2, different time intervals were ordinal variables. A p value <0.05 was considered as significant. The software package "Survival" (R, version 2.14, www.r-project.org) has been used to conduct the statistical analysis.
Results
Demographic information
Sixty-four patients with CP CML at diagnosis and at IM-resistance were identified in the initial international T315I + database and matched with 53 T315I negative counterparts (detailed in Table 1 ). Importantly, in T315I+ patients, the T315I clone was predominant in 42 patients (78%) out of 53 cases evaluable for quantification, over wild-type (31 patients) or other mutated transcripts (11 patients, 21%). In 10 patients (19%) the wildtype clone or another mutated clone were predominant. Significantly more patients had
Interferon-α (IFN) prior to IM in the T315I + group (64% vs. 37.7%, p=0.008), but the duration of IFN treatment did not differ between the two groups (10-12 months, p=0.98).
The initiation of IM occurred after a median of 33 months after diagnosis in the T315I -group vs 63.8 months in the T315I + group, not significantly different (p=0.09). The exposure to the selective agent, IM, and the intervals IM-initiation and IM-resistance were similar. Sixteen patients (30%) had mutations other than T315I in the control group at time of IM-resistance (3 M244V, 2 G250E, 3 D276G, 2 E355G, 3 F359C, 1 F359V, 1 V379I, 1 H396R+F359V as detailed in Table 2 ) and 30% had additional mutations in the
F359C) when the T315I mutation was detected. Forty-seven patients out of 53 had received one or more TKI2 (89%) in the T315I -group and 48/64 patients (75%) in the T315I + group (p=0.1), after a median of 29 and 36 months respectively. The median interval between the occurrence of IM-resistance and the TKI2 initiation (whenever done)
did not differ [9 (T315I -group) and 6 (T315I + group) months, p=0.35]. In the T315I + group, the mutation was detected in 17/64 (26%) of the cases after the initiation of TKI2, although undetectable at IM-resistance. Importantly, the median follow-up from CP CML diagnosis were similar in both groups, approximately 6 years (p=0.61).
Overall and failure-free survival
We analyzed, as depicted in Figures 1A, 1B, Twenty-six deaths in the T315I + group and 14 in the T315I -control group were recorded.
When we analyzed the failure-free survival (as defined previously) of these 2 cohorts from the same starting points, survival was unequivocally significantly worse in patients harboring the T315I for all starting points (p=0.02, p=0.003, p=0.005 respectively, Figure   2A , B, C). Finally, and in order to determine whether the TKI2 might promote the disease by enhancing the selection of T315I cells in vivo, we looked at the survival of patients since TKI2 exposure, according to the moment of detection of the T315I mutation, prior to the exposure to TKI2 (i.e. patients on IM) or after the initiation of TKI2 (Figure 3 ).
Although the overall survival does not seem to differ (p=0.6, data not shown), failure-free survival was significantly worse for patients with a T315I mutation detected after TKI2 initiation (p=0.024), but the number of patients was small. Median interval between the discontinuation of IM and the initiation of the first TKI2 (if any) was 1.04 (0-4.26) months in the T315I + group and 0.02 (0-2.78) month in the T315 -group (p=ns), excluding a deselection phenomenon (18) .
Cox proportional hazard model on OS
The Cox proportional hazard model on OS since IM-resistance was performed in patients analyzing the impact of 7 variables detailed in patients and methods section ( Figure 4A ). We further analyzed in a Cox proportional hazard model the impact of the same variables (except the presence of the T315I mutation) on OS in the population of T315I + patients (n=64, Figure 4B ) exclusively, in an effort to identify favorable or unfavorable factors in this selected subpopulation. Again, the positive impact on OS of the exposure to IFN (p=0.007, HR=0.24) was identified, and an unexpected positive impact on OS of the exposure of T315I + patients to TKI2 was found (p=0.0199, HR=0.3). Age, gender, interval between IM-initiation and resistance did not influence OS in this model.
Discussion
Several studies have suggested that CML patients harboring a T315I mutation have poor prognosis (7, 10, 12, 13) clones while others do not (24) . Patients exposed to IFN treatment for a similar duration, were more frequent in the T315 + group than in the other, although the interval between diagnosis and IM-initiation was longer in the T315I -group. In the Cox models adjusted on OS for the 2 groups and for the T315I + group (Figure 4) , IFN relates to a significant positive impact. In the unmutated IM-resistant group, 20/53 patients had IFN prior to IMresistance but never in combination with IM or alone once IM-resistance had occurred. In the T315I + group, 5 patients had received IFN after the identification of the T315I mutation, 36 before (30 alone prior to IM, 6 in combination with IM, data not shown). We hypothesize that the fact that some patients received IFN after the identification of the T315I mutation, a possible therapeutic option (25) as well as omacetaxine mepesuccinate (25, 26) in patients not eligible for allogeneic stem cell transplantation might explain this positive effect. However, it remains unclear whether IFN exerts a specific activity on the T315I mutated clone (25) or if simply the withdrawal of the selective agent, the TKI, improves the outcome in these patients (18) .
In this matched pair analysis, the presence of the T315I mutation in CP undoubtly impairs overall and failure-free survival ( Figures 1A,B,C and 2A ,B,C). The median OS and FFS were never reached in any case for T315I -patients, and were always reached for T315I + patients. The multivariate analysis adjusted on OS ( Figure 4A ) strengthened such results, in which the presence of the T315I negatively impacted on survival (p=0.023, HR=2.54). These findings suggest that the presence of the mutation, whatever the therapeutic options used in these patients, confers a competitive growth advantage to the CP CML cells. A previous study (27) demonstrated that KD mutations confer poor prognosis to CML patients in CP. In the present study, 30% of the CP patients in the T315I -control group harbored diverse mutations concurring for IM-resistance, however, their OS and FFS remained better than T315I + patients, suggesting that the T315I mutation by itself worsens specifically their prognosis.
TKI-2 as more selecting agents might impact on survival although it is difficult to
analyze this in our study as not all the T315I patients received TKI-2, and some of them received successively one, two and even three TKI-2 (nilotinib, dasatinib, bosutinib). In the comparative group, 30% of the patients were mutated and rescued, in the majority of analysed since the initiation of TKI-2 was significantly worse in the group of patients in whom the T315I mutation was detected after TKI-2 initiation (p=0.024, Figure 3 ), suggesting that these agents, by selecting the T315I + cells even more efficiently than IM would do, might promote a rapid failure in such a situation. The general assumption in this regard would be not to use TKI-2 once a T315I mutation has been detected in IMresistant CP CML patient as recommended (29) .
This study, despite its obvious caveats confirms that the presence of the T315I mutation in IM-resistant CP CML patients impairs OS and FFS. It suggests that the use of TKI2 after the identification of the mutation in IM-resistant patients might selectively impair the FFS of such patients. We believe that the introduction of third generation TKI efficiently targeting 1 st and 2 nd generation resistant patients including T315I + such as ponatinib currently tested in a prospective clinical trial (30) and approved in the US, might help in improving survival for patients remaining ineligible for allogeneic stem cell transplantation.
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GE has given some lectures for Novartis, BMS and is a consultant for Novartis and Pfizer. Depicts the failure-free survival of chronic phase CML patients resistant to IM harbouring a T315I mutation, in months, according the time of detection of the mutation before (plain line) of after (dashed line) the exposure to TKI2. "n" represents the number of patients in each curve. confidence interval exact numbers. Table 1 .
General characteristics of the two paired populations of chronic phase CML patients without and with T315I mutation and compared in a univariate analysis. All data are median value, data in brackets represent the range for each datapoint. Table 2 .
BCR-ABL mutations -other than T315I-identified in the control group of patients resistant to TKI and individual TKI therapeutic sequence (Only 30% of the patients had detectable levels of various types of mutated cells). IM states for imatinib mesylate, MBC for myeloid blast crisis.
